Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide

Two novel oral drugs that target androgen signaling have recently become available for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate inhibits the synthesis of the natural ligands of the androgen receptor, whereas enzalutamide directly inhibits the andr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Pharmacokinet
Asıl Yazarlar: Benoist, Guillemette E., Hendriks, Rianne J., Mulders, Peter F. A., Gerritsen, Winald R., Somford, Diederik M., Schalken, Jack A., van Oort, Inge M., Burger, David M., van Erp, Nielka P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer International Publishing 2016
Konular:
Review Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5069300/
https://ncbi.nlm.nih.gov/pubmed/27106175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-016-0403-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller